SCM
GLUE icon

Sterling Capital Management’s Monte Rosa Therapeutics GLUE Stock Holding History

Sterling Capital Management’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.29K Sell
260
-1,745
-87% -$33K ﹤0.01% 2491
2026
Q1 		$33K Sell
2,005
-7,503
-79% -$143K ﹤0.01% 1808
2025
Q4 		$149K Buy
9,508
+6,290
+195% +$84.8K ﹤0.01% 1390
2025
Q3 		$23.8K Buy
3,218
+2,051
+176% +$10.9K ﹤0.01% 2063
2025
Q2 		$5.26K Buy
1,167
+454
+64% +$2.02K ﹤0.01% 2480
2025
Q1 		$3.31K Sell
713
-611
-46% -$3.75K ﹤0.01% 2367
2024
Q4 		$9.19K Buy
1,324
+1,177
+801% +$8.83K ﹤0.01% 2199
2024
Q3 		$779 Buy
+147
New +$742 ﹤0.01% 2669

Other funds holding GLUE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Sterling Capital Management's GLUE Position: Q2 2026 in Review

Sterling Capital Management reduced its Monte Rosa Therapeutics (GLUE) stake by 87% in Q2 2026, selling an estimated $33K and leaving 260 shares worth $6.29K. The position accounts for ﹤0.01% of the portfolio, ranked #2491.

Sterling Capital Management first reported a position in GLUE in Q3 2024 and has held it in 8 quarters since. The position peaked at $149K in Q4 2025. 193 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

  • Sterling Capital Management held 260 shares of Monte Rosa Therapeutics worth $6.29K as of Q2 2026.
  • Sterling Capital Management sold 1,745 Monte Rosa Therapeutics shares in Q2 2026, an estimated $33K.
  • Monte Rosa Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #2491 holding.
  • Sterling Capital Management first reported a position in Monte Rosa Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • Sterling Capital Management's Monte Rosa Therapeutics position peaked at $149K in Q4 2025.
  • 193 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.